AIM vs. ZIVO, EVAX, APTO, SNTI, BCLI, PMCB, TVGN, CRTX, NKGN, and COEP
Should you be buying AIM ImmunoTech stock or one of its competitors? The main competitors of AIM ImmunoTech include ZIVO Bioscience (ZIVO), Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), Senti Biosciences (SNTI), Brainstorm Cell Therapeutics (BCLI), PharmaCyte Biotech (PMCB), Tevogen Bio (TVGN), Cortexyme (CRTX), NKGen Biotech (NKGN), and Coeptis Therapeutics (COEP). These companies are all part of the "medical" sector.
AIM ImmunoTech (NYSE:AIM) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.
ZIVO Bioscience received 43 more outperform votes than AIM ImmunoTech when rated by MarketBeat users. However, 82.35% of users gave AIM ImmunoTech an outperform vote while only 61.11% of users gave ZIVO Bioscience an outperform vote.
ZIVO Bioscience has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -14,337.62%. ZIVO Bioscience's return on equity of 0.00% beat AIM ImmunoTech's return on equity.
12.0% of AIM ImmunoTech shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 0.0% of AIM ImmunoTech shares are owned by insiders. Comparatively, 13.4% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, AIM ImmunoTech had 4 more articles in the media than ZIVO Bioscience. MarketBeat recorded 4 mentions for AIM ImmunoTech and 0 mentions for ZIVO Bioscience. AIM ImmunoTech's average media sentiment score of 0.56 beat ZIVO Bioscience's score of 0.00 indicating that AIM ImmunoTech is being referred to more favorably in the media.
AIM ImmunoTech has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.
ZIVO Bioscience has lower revenue, but higher earnings than AIM ImmunoTech. ZIVO Bioscience is trading at a lower price-to-earnings ratio than AIM ImmunoTech, indicating that it is currently the more affordable of the two stocks.
Summary
ZIVO Bioscience beats AIM ImmunoTech on 8 of the 15 factors compared between the two stocks.
Get AIM ImmunoTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIM ImmunoTech Competitors List
Related Companies and Tools
